Key Drivers
- Strong margins
- Weak cash flow
- Low leverage
AIAI Summary
ACAD should now be viewed less as a broad pipeline story and more as a concentrated commercial franchise where near-term upside hinges on DAYBUE's U.S. execution and successful European expansion, but the stock's recent run already prices in a lot of that optimism, making concentration and execution risk the key monitor.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong margins
- •Weak cash flow
- •Low leverage
ACAD combines strong annual margins, solid liquidity, and low leverage with weaker cash conversion, a deeply negative retained earnings history, and a much softer recent quarter, making the stock only moderately attractive at current levels.
Price Behavior
Key Price Behavior Insights:
- •Breakout hold
- •Higher lows
- •Near-term overbought
Over the last month, ACAD broke above the $22.60-$23.70 resistance zone, held gains near $25.20-$25.30, and hit a new high at $25.97, keeping momentum bullish but slightly extended.
Sharp climb from $21.43 to $25.97 with a breakout and fresh high
Sentiment & News
Key News Insights:
- •CHMP reversal
- •Sales momentum
- •Pipeline catalyst
Acadia's unexpected positive CHMP opinion for Daybue in Rett syndrome, combined with steady Nuplazid/Daybue sales, supports the stock, but upcoming remlifanserin data and post-rally estimate/valuation risks keep the near-term outlook mixed.
The news is modestly bullish for ACAD near term, but the stock likely needs continued commercial strength or positive pipeline data to extend its recent gains
Similar Companies in Healthcare
Other companies in the same sector with AI ratings